Treatment outcomes for extensively drug-resistant tuberculosis and HIV Co-infection

Emerging Infectious Diseases

Volumn 19, Issue 3, 2013, Pages 416-424

  O'Donnell, Max R ^a,b   Padayatchi, Nesri ^b,d   Kvasnovsky, Charlotte ^c   Werner, Lise ^b   Master, Iqbal ^d   Horsburgh, C Robert ^e,f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e King George V Hospital   (South Africa)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; MORTALITY; PREDICTIVE VALUE; PSYCHOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84874223413     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1903.120998     Document Type: Article

References (38)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva: The Organization; 2011.
2. Dye C, Bassili A, Bierrenbach AL, Broekmans JF, Chadha VK, Glaziou P, et al. Measuring tuberculosis burden, trends and the impact of control programmes. Lancet Infect Dis. 2008;8:233-43. http://dx.doi.org/10.1016/S1473-3099(07)70291-8
3. Chaisson RE, Martinson N. Tuberculosis in Africa: combating an HIV-driven crisis. N Engl J Med. 2008;358:1089-92. http://dx.doi.org/10.1056/NEJMp0800809
4. Horsburgh CR Jr. The global problem of multidrug-resistant tuberculosis: the genie is out of the bottle. JAMA. 2000;283:2575-6. http://dx.doi.org/10.1001/jama.283.19.2575
5. Raviglione MC, Smith I. XDR Tuberculosis: implications for global public health. N Engl J Med. 2007;356:656-9. http://dx.doi.org/10.1056/NEJMp068273
6. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. http://dx.doi.org/10.1016/S0140-6736(06)69573-1
7. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196:S86-107. http://dx.doi.org/10.1086/518665
8. Extensively drug-resistant tuberculosis (XDR TB): recommendations for prevention and control [in English and French]. Wkly Epidemiol Rec. 2006;81:430-2.
9. O'Donnell MR, Jarand J, Loveday M, Padayatchi N, Zelnick J, Werner L, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010;153:516-22.
10. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): global report on surveillance and response. Geneva: The Organization; 2010.
11. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80-6. http://dx.doi.org/10.1164/rccm.200907-0989OC
12. O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis. 2009;13:855-61.
13. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-807. http://dx.doi.org/10.1016/S0140-6736(10)60492-8
14. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR Morb Mortal Wkly Rep. 2007;56:250-3.
15. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnik CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640-5.
16. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791-4. http://dx.doi.org/10.1136/thx.2006.058867
17. Reisner BS, Gatson MA, Wood GL. Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn Microbiol Infect Dis. 1995;22:325-9. http://dx.doi.org/10.1016/0732-8893(95)00147-7
18. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol. 2006;44:688-92. http://dx.doi.org/10.1128/JCM.44.3.688-692.2006
19. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009;30:685-99. http://dx.doi.org/10.1016/j.ccm.2009.08.010
20. Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, der Walt ML. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011;57:146-52. http://dx.doi.org/10.1097/QAI.0b013e31821190a3
21. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-81. http://dx.doi.org/10.1056/NEJMoa1013911
22. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-91. http://dx.doi.org/10.1056/NEJMoa1013607
23. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492-501. http://dx.doi.org/10.1056/NEJMoa1014181
24. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-92. http://dx.doi.org/10.1164/rccm.201001-0077OC
25. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-405. http://dx.doi.org/10.1056/NEJMoa0808427
26. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151-60. http://dx.doi.org/10.1056/NEJMoa1112433
27. Jassal MS, Bishai WR. Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis. 2010;50(Suppl 3):S156-64. http://dx.doi.org/10.1086/651486
28. Jeon DS, Kim DH, Kang HS, Hwang SH, Min JH, Kim JK, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2009;13:594-600.
29. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359:563-74. http://dx.doi.org/10.1056/NEJMoa0800106
30. Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: A 13-year experience. PLoS ONE. 2011;6:e19399. http://dx.doi.org/10.1371/journal.pone.0019399
31. Masjedi MR, Tabarsi P, Baghaei P, Jalali S, Farnia P, Chitsaz E, et al. Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. Int J Infect Dis. 2010;14:e399-402. http://dx.doi.org/10.1016/j.ijid.2009.07.002
32. Balabanova Y, Radiulyte B, Davidaviciene E, Hooper R, Ignatyeva O, Nikolayevskyy V, et al. Survival of drug-resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open. 2011;1:e000351. http://dx.doi.org/10.1136/bmjopen-2011-000351
33. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13:780-2. http://dx.doi.org/10.3201/eid1305.070200
34. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA. 2008;300:2153-60. http://dx.doi.org/10.1001/jama.300.18.2153
35. Wallengren K, Scano F, Nunn P, Margot B, Buthelezi SS, Williams B, et al. Drug-resistant tuberculosis, Kwazulu-Natal, South Africa, 2001-2007. Emerg Infect Dis. 2011;17:1913-6. http://dx.doi.org/10.3201/eid1710.100952
36. Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2011;17:510-3. http://dx.doi.org/10.3201/eid1703.101363
37. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 Update. Geneva: The Organization; 2011.
38. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:6-14. http://dx.doi.org/10.1086/653115